AI-ACCELERATED DRUG DISCOVERY

Focused On-demand Library for Alpha-1-acid glycoprotein 1

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.

From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.

The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.

We use our state-of-the-art dedicated workflow for designing focused libraries for enzymes.

 Fig. 1. The sreening workflow of Receptor.AI

It includes comprehensive molecular simulations of the catalytic and allosteric binding pockets and the ensemble virtual screening accounting for their conformational mobility. In the case of designing modulators, the structural changes induced by reaction intermediates are taken into account to leverage activity and selectivity.

Key features that set our library apart include:

  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.
  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.
  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.
  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.

partner

Reaxense

upacc

P02763

UPID:

A1AG1_HUMAN

Alternative names:

Orosomucoid-1

Alternative UPACC:

P02763; B7ZKQ5; Q5T539; Q5U067; Q8TC16

Background:

Alpha-1-acid glycoprotein 1, also known as Orosomucoid-1, plays a crucial role as a transport protein in the bloodstream. It uniquely binds to various ligands within its beta-barrel domain, including synthetic drugs, thereby influencing their distribution and availability in the body. This protein is pivotal in modulating the immune system's activity during acute-phase reactions, showcasing its importance in immune response regulation.

Therapeutic significance:

Understanding the role of Alpha-1-acid glycoprotein 1 could open doors to potential therapeutic strategies. Its ability to interact with synthetic drugs and modulate the immune system highlights its potential as a target for developing novel therapeutic agents aimed at enhancing drug efficacy and modulating immune responses.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.